

**PATENT AGENT**

Portland Office
503.473.0850
jodi.connolly@klarquist.com

EDUCATION

Ph.D., Department of Microbiology and Immunology, Vanderbilt University, 2001

B.S. with Honors in Biology, minor in Chemistry, Willamette University, 1996

ADMISSIONS

U.S. Patent and Trademark Office, 2003 (Reg. No. 54,044)

PRACTICE AREAS

Patents

TECHNOLOGIES

Life Sciences & Biotechnology

Jodi L. Connolly, Ph.D.

Jodi is a patent agent in the firm's Life Sciences and Biotechnology practice group where she focuses on preparing and prosecuting U.S., international, and foreign patent applications. She also counsels clients on other matters relating to patents, including planning and managing patent portfolios and performing patentability analyses.

Jodi's expertise includes many areas of biotechnology, including virology, immunology, vaccines, oncology, monoclonal antibodies, antibody conjugates, chimeric antigen receptors (CARs) and CAR T cells, cancer immunotherapy, cancer diagnostics, molecular biology, genetics, biochemistry, gene therapy, RNA interference, and antisense technology. Prior to joining Klarquist, Jodi worked as a patent agent for several years at other firms and at a pharmaceutical company, where she managed patent portfolios and prosecuted patent applications in the field of antisense technology. She also previously worked as a post-doctoral research associate at The Scripps Research Institute studying the interaction of adenovirus vectors with the innate immune system and as a post-doctoral research fellow at the Vanderbilt University Medical Center where she studied induction of apoptosis by reovirus, a double-stranded RNA virus.

Jodi joined Klarquist as a patent agent in 2007.

Professional Experience

- Ionis Pharmaceuticals
Carlsbad, California
Senior Patent Agent, 2003 – 2007
Responsibilities included managing patent portfolios in the field of antisense technology and preparing and prosecuting U.S. and international patent applications.
- Fish and Richardson
San Diego, California
Patent Agent, 2003
Practice emphasized patent prosecution in biotechnology, including gene therapy, molecular biology, biochemistry, virology, immunology, and medical devices.
- Heller Ehrman White and McAuliffe
San Diego, California
Scientific Advisor/Patent Agent, 2002 – 2003
Practice emphasized patent prosecution in biotechnology, including gene therapy, molecular biology, biochemistry, virology, immunology, and medical devices.

- The Scripps Research Institute
La Jolla, California
Research Associate, 2001 – 2002
Studies focused on the interaction of adenovirus with cellular factors involved in the host innate immune response in order to better design an adenoviral gene therapy vector.
- Vanderbilt University Medical Center
Nashville, Tennessee
Graduate Student and Postdoctoral Research Fellow, 1996 – 2001
Research focused on elucidating the mechanisms by which double-stranded RNA viruses induce cell death and identifying viral and cellular components that result in viral pathogenesis in host organisms.

Professional Activities

- Member, American Intellectual Property Law Association

Presentations & Publications

- S.E. Rodgers, J.L. Connolly, J.D. Chappell, and T.S. Dermody. 1998. Reovirus growth in cell culture does not require the full complement of viral proteins: Identification of a s1s-null mutant. *J. Virol.* 72:8597-8604.
- J.L. Connolly, S.E. Rodgers, P. Clarke, D.W. Ballard, L.D. Kerr, K.L. Tyler, and T.S. Dermody. 2000. Reovirus-induced apoptosis requires activation of transcription factor NF- κ B. *J. Virol.* 74:2981-2989.
- G.J. Poggioli, C.J. Keefer, J.L. Connolly, T.S. Dermody, and K.L. Tyler. 2000. Reovirus-induced G2/M cell cycle arrest requires s1s and occurs in the absence of apoptosis. *J. Virol.* 74:9562-9570.
- E.S. Barton, J.L. Connolly, J.C. Forrest, and T.S. Dermody. 2001. Utilization of sialic acid as a coreceptor enhances reovirus attachment by multi-step adhesion strengthening. *J. Biol. Chem.* 276:2200-2211.
- E.S. Barton, J.C. Forrest, J.L. Connolly, J.D. Chappell, F.J. Schnell, A. Nusrat, C.A. Parkos, and T.S. Dermody. 2001. Identification of junction adhesion molecule as a reovirus receptor. *Cell* 104:441-451.
- J.L. Connolly, E.S. Barton, and T.S. Dermody. 2001. Reovirus binding to cell-surface sialic acid potentiates virus-induced apoptosis. *J. Virol.* 75:4029-4039.
- E.S. Barton, J.D. Chappell, J.L. Connolly, J.C. Forrest, and T.S. Dermody. 2001. Reovirus receptors and apoptosis. *Virology* 190:173-180.
- J.L. Connolly and T.S. Dermody. 2002. Virion Disassembly is Required for Reovirus-Induced Apoptosis. *J. Virol.* 76:1632-1641.
- M. Filippova, H. Song, J.L. Connolly, Terence S. Dermody, and P.J. Duerksen-Hughes. 2002. The human papillomavirus 16 E6 protein binds to TNF R1 and protects cells from TNF-induced apoptosis. *J. Biol. Chem.* 277:21730-21739
- E.S. Barton, B.E. Youree, D.H. Ebert, J.C. Forrest, J.L. Connolly, T. Valyi-Nagy, K. Washington, J.D. Wetzel, and T.S. Dermody. 2003. Utilization of sialic acid as a coreceptor is required for reovirus-induced biliary disease. *J. Clin. Invest.* 111:1823-1833
- S.M. O'Donnell, M.W. Hansberger, J.L. Connolly, J.D. Chappell, M.J. Watson, J.M. Pierce, J.D. Wetzel, W. Han, E.S. Barton, J.C. Forrest, T. Valyi-Nagy, F.E. Yull, T.S. Blackwell, J.N. Rottman, B. Sherry and T.S. Dermody. 2005. Organ-specific roles for transcription factor NF- κ B in reovirus-induced apoptosis and disease. *J. Clin. Invest.* 115:2341-2350

- M. Iacobelli-Martinez, R.R. Nepomuceno, J. Connolly, G.R. Nemerow. CD46-utilizing adenoviruses inhibit C/EBPbeta-dependent expression of proinflammatory cytokines, 2005 J. Virol. 79:11259-68.

Representative Patents

- Anti-fXI antibodies and methods of use (8,388,959)
- Engineered antibody constant domain molecules (8,580,927)
- Rabies virus-based recombinant immunocontraceptive compositions and methods of use (8,524,247)
- Methods for modulating embryonic stem cell differentiation (8,617,813)
- Recombinant Rift Valley fever (RVF) viruses and methods of use (8,673,629)
- Differentially expressed microRNAs as biomarkers for the diagnosis and treatment of Sjögren's syndrome (8,785,414)
- Tolerizing agents (7,910,113)
- Th1-associated microRNAs and their use for tumor immunotherapy (8,486,911)
- Tetravalent influenza vaccine and use thereof (8,513,006)
- Nitrite and nitrite-metheme therapy to detoxify stroma-free hemoglobin based blood substitutes (8,551,536)